NordICC at 13 Years: Colonoscopy Prevents CRC, but Mortality Benefit Remains Uncertain: The Lancet | September 2026

Introduction:

Colonoscopy can detect and remove precancerous lesions, but randomised evidence demonstrating its population-level impact remains limited. NordICC provides long-term data on whether invitation to a single screening colonoscopy reduces colorectal cancer (CRC) incidence and mortality.

Why was this study needed?

Most evidence supporting screening colonoscopy has been observational.

Long follow-up is required to capture cancer-prevention benefits.

Screening effectiveness depends heavily on actual participation.

Key Findings:

84,583 adults aged 55–64 years were randomized to colonoscopy invitation or usual care.

At 13 years, CRC incidence was 1.46% vs 1.80%, a 19% relative reduction.

Only about 42% of invited participants underwent colonoscopy.

Estimated per-protocol analysis suggested approximately 45% lower CRC incidence among those who underwent screening.

CRC mortality was 0.41% vs 0.47% and remained statistically inconclusive.

The modest intention-to-screen effect therefore partly reflects low colonoscopy uptake, rather than lack of efficacy of colonoscopy itself.

Longer follow-up may be needed to clarify mortality benefit.

Bottom Line:

NordICC confirms that colonoscopy screening reduces CRC incidence. Its population-level benefit is strongly influenced by participation, while a definitive CRC mortality advantage remains unproven at 13 years.